Search
Teledermatology and its role in strengthening skin cancer pathways
Skin cancer services continue to operate under sustained pressure. Rising incidence, heightened public awareness and predictable seasonal surges all contribute to increased demand, particularly within urgent suspected cancer pathways. Against this backdrop, many systems have turned to teledermatology as a way of supporting earlier clinical decision making and reducing unnecessary pressure on secondary care.
The value and impact of a teledermatology service depends on whether pathways are clinically led, well governed and properly integrated into existing services. Where these elements come together, teledermatology can support timely assessment, improve patient experience and make better use of specialist capacity.
Experience embedded in delivery
Xyla delivers teledermatology as part of a wider set of elective, diagnostic and digital services provided in partnership with the NHS. As a CQC‑registered provider and part of Acacium Group, this work sits within a broader organisational context shaped by long‑standing collaboration with acute trusts and integrated care systems.
Within dermatology, more than 95,000 referrals have now been triaged through Xyla’s teledermatology services, alongside wider elective activity supporting over 261,000 patients in 2025. That experience informs how pathways are structured, how governance is established and how services are designed to operate consistently during periods of heightened demand.
Teledermatology as an early clinical decision point
In Frimley ICB, teledermatology functions as an early decision point within the dermatology pathway, including urgent suspected skin cancer referrals. GP referrals are received electronically and reviewed by UK registered consultant dermatologists, with same‑day processing built into routine practice.
Where GP supplied images are sufficient, virtual triage allows for prompt and confident clinical decisions. When further visual information is required, patients are contacted and booked into medical photography appointments delivered by trained staff. This ensures that assessment continues without delay and that consultant decisions are supported by consistent, high‑quality imagery.
All urgent suspected cancer referrals are triaged within a two-day service level agreement, providing early clarity for patients and supporting onward pathway planning at a time when uncertainty can be particularly distressing.
What the referral flows show
Over time, the referral patterns emerging from this model illustrate how early consultant triage shapes pathway flow. In Frimley, just over half of urgent suspected cancer referrals progress into secondary care following virtual assessment. A smaller proportion are categorised as urgent or routine, while around 40% are managed safely in the community or discharged back to general practice with an agreed treatment plan.
Seen together, these outcomes show how teledermatology can act as a filter rather than a funnel. Around 60% of referrals do not progress to hospital clinics, easing pressure on secondary care while preserving rapid access for patients who need further investigation. At the same time, all urgent suspected cancer referrals continue to meet the two-day triage standard.
The role of medical photography
IImage quality remains one of the defining factors in remote dermatology assessment. Inconsistent or poor‑quality photographs can introduce uncertainty and undermine clinical confidence. For this reason, medical photography is embedded as a core component of the pathway rather than used selectively.
When required, photography appointments are arranged promptly, with defined turnaround times for urgent suspected cancer, urgent and routine referrals. This supports consistent consultant decision making and reduces reliance on variable primary care images, strengthening the overall reliability of remote triage.
Governance designed to support growth
As referral volumes rise, particularly through late spring and summer, maintaining clinical quality becomes increasingly important. Teledermatology activity within the pathway is overseen by consultant dermatology clinical leads, with governance processes designed to support both safety and scale.
Consultants joining the service initially work within supervised activity thresholds, supported by audit and peer review. Concordance with British Association of Dermatologists guidance is monitored, with processes in place to review decision making and identify any potential missed cancers. This enables capacity to increase in a controlled way, without compromising clinical standards as demand grows.
Planning for seasonal demand
Seasonal variation in skin cancer referrals is well recognised. Rather than responding reactively, workforce planning is structured around anticipated peaks. A substantive pool of UK‑registered consultant dermatologists is supported by phased onboarding, flexible sessional working and real‑time monitoring of activity and demand.
Capacity can be mobilised quickly when required, allowing services to respond to backlogs, rising referral volumes or seasonal surges without the long lead‑in times associated with traditional outpatient expansion.
Effects across the wider system
The influence of a well‑designed teledermatology pathway extends beyond dermatology clinics. Patients benefit from faster initial assessment and clearer outcomes at a time when anxiety is often high. Many avoid unnecessary hospital visits while still receiving specialist input, improving experience and reassurance.
GPs receive timely consultant advice and structured outcomes that support ongoing care. Secondary care teams are better able to focus on patients whose needs require face‑to‑face assessment and intervention. At a system level, teledermatology supports backlog reduction, demand management and more resilient use of specialist capacity.
A mature role within modern pathways
Used thoughtfully, teledermatology becomes a dependable part of skin cancer pathways rather than a parallel service. Consultant‑led triage, integrated medical photography and robust governance allow it to support early diagnosis, reduce avoidable pressure on secondary care and improve patient experience simultaneously.
For systems exploring how teledermatology could support their own skin cancer pathways, there is value in understanding how these models operate in practice, how quickly they can be mobilised and how they can be shaped around local needs. Xyla works with NHS partners to explore this in a collaborative, practical way, focusing on safety, flow and sustainability rather than one‑size‑fits‑all solutions.
If you would like to discuss how teledermatology could support your skin cancer pathway, reduce pressure on services or improve patient experience within your system, please reach out to our expert team.
Contact us
Have any questions about our services? Whether you’re wondering about how we can help your health goals, or assist your healthcare organisation, we’d love to hear from you.
Related Stories
Share this article
Contact us
Have any questions about our services? Whether you’re wondering about how we can help your health goals, or assist your healthcare organisation, we’d love to hear from you.
Get in touch